Vaccines

Drama encases ACIP, CDC amid lawsuit, deadline

Wed, 25 Mar 2026 12:00:00 -0400

Chaos continues at the U.S. CDC and its Advisory Committee on Immunization Practices (ACIP) with the resignation of ACIP member Robert Malone and the impending deadline for the president to nominate a new CDC director following the dramatic exit last year of Susan Monarez and months of acting directors.

The domino effect of cutting mRNA vaccine research

Mon, 15 Sep 2025 09:00:00 -0400

In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing therapies for viral infections, cancer, and genetic conditions. What happens to mRNA innovation when funding dries up? This series explores how reductions in funding could impact mRNA technology, affecting innovation, research and future therapies.

South Korea INDs: Pimedbio, Sillajen, Genosco, SK Bio, Ami

Tue, 09 Sep 2025 11:00:00 -0400

Several South Korean biotech and biopharmaceutical companies completed IND submissions or won nods to start clinical trials in either the U.S. or South Korea, including SK Bioscience Co. Ltd., Genosco Inc., Pimedbio Inc., Sillajen Inc. and Ami Pharm Co. Ltd.

South Korea INDs: Pimedbio, Sillajen, Genosco, SK Bio, Ami

Wed, 03 Sep 2025 11:00:00 -0400

A potentially therapeutic vaccine against chronic hepatitis B

Wed, 06 Aug 2025 09:00:00 -0400

Chronic infection with hepatitis B virus affects around a quarter of a billion people globally, and it can increase risk of cirrhosis and hepatocellular carcinoma. Such infection is typically treated with nucleoside analogues, which do not eliminate it entirely. Therefore researchers have been searching for effective vaccines that could work not only in the classical sense of preventing infection from becoming chronic, but also in a therapeutic sense of curing already chronic infection.

Researchers file patent for microfluidic patch-pump drug delivery platform

Thu, 12 Jun 2025 12:00:00 -0400

Researchers from Virginia Polytechnic Institute and State University filed for protection of their development of a slim, painless, and affordable microfluidic infusion pump device for the continuous transdermal delivery of drugs.

mRNA vaccine could prevent and treat HPV-related cancer

Wed, 03 Apr 2024 09:00:00 -0400

A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment.

PIV5-vectored OspA-based vaccine provides long-term protection against B. burgdorferi infection in mice

Wed, 21 Feb 2024 09:00:00 -0500

Immuno Technologies Inc. and affiliated organizations have published preclinical data on a novel parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease.

Evaxion Biotech and MSD complete initial phases of bacterial vaccine collaboration

Wed, 21 Feb 2024 09:00:00 -0500

Using its proprietary AI-Immunology platform, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.

Multivalent mRNA vaccine prevents mpox disease

Fri, 16 Feb 2024 09:00:00 -0500

A vaccine based on messenger RNA (mRNA) technology against four surface proteins of the envelope and the inner membrane of the mpox virus (MPXV) demonstrated its efficacy in two animal models. Biontech SE scientists designed and tested two different combinations of antigens in mice and macaques for the two infective forms of the virus. One of them showed better results for its evaluation in clinical trials preventing the disease.

Vaxess device improves application of vaccine patches

Tue, 09 Jan 2024 11:00:00 -0500

Vaxess Technologies Inc. seeks patent protection for devices that enable the reliable application of silk fibroin-based microneedle medicament patches used for delivering small molecule drugs, vaccines, peptides, biologics, antibodies, hormones or other materials into or through the skin.

Off-target immune response from modified mRNA impacts future development

Thu, 07 Dec 2023 09:00:00 -0500

The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it encodes has been found on some occasions to cause ribosomal frameshifting.

Off-target immune response from modified mRNA impacts future development

Wed, 06 Dec 2023 12:00:00 -0500

Lenti-HPV-07 vaccine achieves complete HPV-induced tumor eradication in the preclinical setting

Thu, 28 Sep 2023 09:00:00 -0400

Among all human papillomavirus (HPV) types described so far, the two most abundant – HPV16 and HPV18 – are responsible for 71% of all cervical cancers. The vaccines currently used are effective in preventing viral infection, but have no effect on already infected or maligned cells.

Double-double-duty EBV vaccine shows promise in animal models

Wed, 09 Aug 2023 09:00:00 -0400

An experimental vaccine that contained antigens of both lytic and latent phases of Epstein-Barr virus (EBV), and induced both an antibody and a T cells response, was able to generate broad and long-lasting immunity against EBV in mouse models of infection. Researchers from the QIMR Berghofer Medical Research Institute and Elicio Therapeutics Inc. reported those results online in Nature Communications on Aug. 8, 2023.

For some viruses, the challenge to developing a vaccine is their rapid mutation rate. This is the major challenge to developing an HIV vaccine or a universal flu vaccine. EBV is different. Its superpower is its ability to hide.

IAS 2023: Vaccines and broadly neutralizing antibodies bring cure for HIV one step closer

Tue, 01 Aug 2023 12:00:00 -0400

Although huge strides have been made with antiretroviral therapy (ART) and prevention since HIV was first reported 42 years ago, there is still not an effective preventive vaccine or a scalable cure for those living with HIV. But broadly neutralizing antibodies (bNAbs) look to be a further step down the pathway to a cure, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.

New mRNA malaria vaccine could be more effective than antibody strategies targeting liver memory T cells

Thu, 27 Jul 2023 09:00:00 -0400

An mRNA vaccine candidate that acts in the liver by recruiting memory T cells could be the key against malaria, according to a study in mice that demonstrated its efficacy by including a natural killer T (NKT) cell agonist.

IAS 2023: Vaccines and broadly neutralizing antibodies bring cure for HIV one step closer

Wed, 26 Jul 2023 11:00:00 -0400

PRX-123, a dual Aβ/tau peptide vaccine that clears Aβ plaques in brains of AD mice

Fri, 21 Jul 2023 09:00:00 -0400

Since both amyloid-β (Aβ) and tau are involved in the progression of Alzheimer’s disease (AD), it is believed that simultaneous disruption of these...

MDCK-QIV influenza virus vaccine demonstrates safety and efficacy in preclinical setting

Fri, 21 Jul 2023 09:00:00 -0400

Researchers from Wuhan Institute of Biological Products Co. Ltd. and affiliated organizations presented preclinical data for the novel Madin...

Evaxion develops genetic adjuvant technology to boost immune response to viral, bacterial and cancer vaccines

Fri, 26 May 2023 09:00:00 -0400

Evaxion Biotech A/S has unveiled the technology behind its proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.

Defence Therapeutics engineers Accum-mRNA cancer vaccine

Wed, 12 Apr 2023 09:00:00 -0400

Defence Therapeutics Inc. says it has successfully established a strategy conjugating mRNA molecules to Accum, the company’s core technology that enables precision delivery of vaccine antigens or antibody-drug conjugates in their intact form to target cells.

Ocean Biomedical targets parasite protein PfGARP to tackle malaria

Wed, 22 Mar 2023 09:00:00 -0400

Ocean Biomedical Inc. has outlined details of its novel approach to treating malaria. Building on...

Virally driven cancers are mRNA vaccines’ first, and next, frontier

Mon, 06 Mar 2023 09:00:00 -0500

In a striking demonstration of how the success of mRNA vaccines against COVID-19 has opened up the potential of the technology in cancer, mice that cleared a tumor after a single administration of an mRNA vaccine, also cleared a second tumor without receiving further immunization. This display of potent immunogenicity formed part of a head-to-head study of three different mRNA technology platforms in human papillomavirus (HPV)-16 associated tumors.

Path to a broadly effective HIV vaccine is coming into focus

Thu, 23 Feb 2023 09:00:00 -0500

In the larger picture, the fight against HIV has been a triumph of modern medicine. A patient diagnosed with HIV in the 1980s had a remaining life expectancy of 1 to 2 years. In 2023, they can expect to live another half century. But so far, an HIV vaccine has remained elusive. In the newest phase III failure, Janssen Pharmaceutical Cos. of Johnson & Johnson closed down its Mosaico trial more than a year ahead of schedule, following a data and safety monitoring board’s (DSMB) report saying the study was not expected to hit its primary endpoint.

Oragenics reports toxicology findings with NT-CoV2-1 intranasal COVID-19 vaccine candidate

Fri, 23 Dec 2022 09:00:00 -0500

Oragenics Inc. has announced results from its...

Recbio's novel adjuvanted recombinant shingles vaccine REC-610 cleared to enter clinic in Philippines

Mon, 19 Dec 2022 09:00:00 -0500

Jiangsu Recbio Technology Co. Ltd. has received clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC-610, from the Food and Drug Administration of the Philippines. A phase I trial will be conducted in healthy volunteers.

Biovaxys reports outcomes from pan-sarbecovirus vaccine animal study

Mon, 19 Dec 2022 09:00:00 -0500

Biovaxys Technology Corp. has announced...

Antibody effector functions predict protection against RSV re-infection

Tue, 13 Dec 2022 09:00:00 -0500

Both neutralizing antibodies and antibody effector functions are needed for protection against re-infection with respiratory syncytial virus (RSV), which may explain why it has been challenging to design an effective vaccine against the virus. As reported in the Dec. 12, 2022, issue of Cell, researchers carried out a human challenge study where volunteers were given a candidate vaccine for RSV, Ad26, or placebo.

Emergex advances chikungunya vaccine development with generation of CHIKV ligandome

Tue, 29 Nov 2022 09:00:00 -0500

Emergex Vaccines Holding Ltd. has generated a chikungunya virus (CHIKV) ligandome, the first major milestone in the development of the company's CD8+ T-cell CHIKV adaptive vaccine candidate. Using an immunoproteomics approach, naturally presented MHC Class I-restricted peptides on the surface of a human leukocyte antigen (HLA)-typed cell line infected with CHIKV virus were extracted and identified.